Morgan Stanley Sees Sapien Becoming Leading Product Line for Edwards Lifesciences
In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Edwards Lifesciences (NYSE: EW).
In the report, Morgan Stanley noted, “Sapien should prove to be the leading product line in transcatheter valves into '14 and beyond, supported by clinical data. The TAVR market is likely to continue its expansion, supported by better budgets in Europe, favorable clinical data in lower risk populations, and more deliverable products. A mitral replacement program could drive upside given the larger potential patient pool relative to the aortic space. Higher valve revenue mix supports higher GMs.”
Edwards Lifesciences closed on Thursday at $80.27.
Latest Ratings for EW
|Nov 2014||Sterne Agee||Downgrades||Buy||Neutral|
|Oct 2014||Morgan Stanley||Maintains||Equal-weight|
|Oct 2014||CRT Capital||Maintains||Buy|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.